FDA OKs Canagliflozin to Curtail Diabetic Kidney Disease FDA OKs Canagliflozin to Curtail Diabetic Kidney Disease

Results of CREDENCE lead to FDA approval for canagliflozin to slow kidney disease progression and reduce the risk of heart failure hospitalization in adults with type 2 diabetes.FDA Approvals

Source: Medscape Cardiology Headlines - September 30, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news